TMBRQ — Trex Wind-Down Share News
0.000.00%
Last trade - 00:00- $0.00m
- -$2.52m
- $0.08m
Timber Pharma rises on positive EMA opinion for skin disorder therapy
Brief: Timber Pharmaceuticals Receives Positive Opinion On Orphan Designation From European Medicines Agency For Tmb-001 For Treatment Of Autosomal Recessive Congenital Ichthyosis
Brief: Timber Pharmaceuticals Announces Notification Of NYSE American Continued Listing Deficiency
Brief: Timber Pharmaceuticals To Highlight Phase 2B Control Study Results In Multiple Presentations At 31St Eadv Congress
Brief: Timber Pharmaceuticals Announces Publication Of Results From Phase 2B Control Study Of FDA-Designated Breakthrough Therapy Tmb-001
Brief: Timber Pharmaceuticals Provides Business Update And Announces Second Quarter 2022 Financial Results
Brief: Timber Pharmaceuticals Announces Pricing Of $8.0 Million Public Offering
Brief: Timber Says First Patients Enrolled In Phase 3 Ascend Clinical Trial Evaluating TMB-001 In Congenital Ichthyosis
U.S. STOCKS ON THE MOVE-Kirkland's, Snap, casino stocks
U.S. STOCKS ON THE MOVE-Chinese ADRs, DexCom, Mullen Automotive
Brief: Timber Pharmaceuticals Receives FDA Breakthrough Therapy Designation For TMB-001 For The Treatment Of Congenital Ichthyosis
U.S. STOCKS ON THE MOVE-Outlook Therapeutics, airline and crypto stocks
Timber Pharma surges on FDA breakthrough therapy tag for skin disorder therapy
Brief: Timber Pharmaceuticals Announces First Quarter 2022 Financial Results
Timber Pharma gains on FDA fast-track tag for rare skin disorder therapy
Brief: Timber Pharma Reports Fast Track Designation Granted By FDA For TMB-001 In Severe Subtypes Of Congenital Ichthyosis
Brief: Timber Pharmaceuticals Inc - Expects To Initiate A Phase 3 Clinical Trial For TMB-001 In Q2 Of 2022
Brief: Timber Pharmaceuticals Provides Business Update And Announces Fourth Quarter And Year End 2021 Financial Results
Timber Pharma efficiently targeting niche dermatology markets - Wainwright